Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Exploring the role of FXYD family (FXYD domain-containing ion transport regulators) proteins in health and disease The FXYD ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases ...

Exelixis, Inc. EXEL reported preliminary, unaudited financial results for fiscal year 2025, issued financial guidance for ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

Medical science can typically provide a clear explanation of the intricacies of the human body. However, there are times when ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

Men with newly diagnosed multiple myeloma are twice as likely as women to have stage III disease, with more kidney damage and ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...